Glioblastoma remains one of the most aggressive and difficult-to-treat forms of brain cancer, with recurrence posing a significant challenge for patients and researchers alike. In this episode of Moving Medicine Forward, Jeremy Schrand sits down with Moya Daniels, Vice President, Head of Regulatory and QA at Optieum Biotechnologies, to discuss the company's novel CAR-T cell therapy program, OPTF01, and its potential to transform treatment for recurrent glioblastoma. Moya shares insights into the

Type 7s chase new experiences, keep every option open, and often avoid sitting still with discomfort — but growth happens when they borrow from their resource point. This week Zach and Laura explore what it looks like when a 7 taps into Type 5 (slowing down, going deep instead of wide, and finding focus and clarity in stillness instead of constant motion).See omnystudio.com/listener for privacy information.

In this episode of Scientists, Unedited, host Eirini Vamva, PhD, talks with Bruce Levine, PhD, about his personal life and career in cell therapy. Dr. Levine talks about finding his way into immunology, learning from pivotal mentors, and following the unexpected opportunities that led him to the forefront of cell therapy. He reflects on the patients who inspired his work and the teamwork behind major breakthroughs. He also shares the story behind a CAR-T song he helped write and talks about some of

Bioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medicine, food, agriculture, manufacturing, climate, and more.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shai Melcer, head of the national bioconvergence programme at Israel Innovation Authority, for a conversation exploring bioconvergence broadly. Melcer discusses the foundations, goes into detail about

We welcomed Mandana Honu onto the BioHub podcast

Canada has a strong research base, but turning discoveries into lasting economic and societal value is not always easy. In this episode of AUTM on the Air, I talk with Sarrah Lal about the launch of AUTM’s Canadian Public Policy Advisory Committee, or CPPAC. As the committee’s inaugural chair, Sarrah brings insight into why the group was created and why this is a timely moment to look more closely at the policies that shape research commercialization across Canada.We discuss the gaps that can slow

From student flat kitchen politics to backpacking in South East Asia - living with serious allergies isn't just about reading food labels, it's about the mental load and preparation that comes with it. For Anaphylaxis Awareness Week 2026, we’re shining a spotlight on what true inclusivity looks like. Living with serious allergies shouldn’t put invisible barriers in the way of university life, travel, dating, or starting a career. In this episode, our Information Officer Emilia speaks with two young

In this episode of Rethink Imaging, host Chris St. John sits down with medical physics legend Dr. Ehsan Samei to dissect why medical imaging often treats patients as population aggregates rather than individuals. Dr. Samei breaks down the hidden "degrees of freedom" in scan acquisitions, challenges the industry's reliance on rigid manufacturer default protocols, and outlines how physicists and radiologists can work together to deliver truly personalized, patient-centric care.

In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President & CEO of Cerenome, and Russell Bradley, President & General Manager of CNSide Diagnostics.We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem.Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell

PRIMER: Rabies*For free access to the podcast newsletter click here*

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026! This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless de...

Hey! I'd love to hear your thoughts, send me a voice note.In this second edition of the ANT Neurocast, ANT Neuro CEO Dr. Martijn Schreuder speaks with Dr. Jaime Adán Manes — consultant psychiatrist in Madrid and co-founder and Chief Science Officer of Connectoma Neurotech — about how non-invasive brain stimulation is being personalized to treat depression more effectively.Trained in medicine at the Complutense University of Madrid, with a psychiatry residency at Hospital Universitario de La Princesa

The scarecrow watches over the field, but does it watch us back? Does it keep the birds away, or does it deter darker fiends from these haunted lands? Join Robert and Joe for a Halloween-season look at the science, culture and folklore of scarecrows.See omnystudio.com/listener for privacy information.

We know all about how things exist in the three dimensions of length, width, and height. Physicists often talk about time as a fourth dimension, but what if there were a fourth spatial dimension — another direction entirely? How on earth would we picture that?Mathematicians use topology to visualize abstract spaces in higher dimensions. Maggie Miller at the University of Texas at Austin explores what happens when knots encounter an extra dimension. Familiar tangled loops behave in

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the most important drug companies in the world. Over $15 billion in deals with GSK and Novo Nordisk. The world's top clinical trial sponsor. One of the top five drug pipelines globally. All from a city most people can't find on a map. We break down how Hengrui made the pivot from g...

September 30 edition, released October 1. Date references in the audio are anchored to September 30.Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weight loss vs 14.8% for tirzepatide in a secondary Phase 2b comparison, while more patients stopped over adverse events. Rafael Holdings' Trappsol Cyclo missed its Phase 3 TRANSPORT-NPC goal in Niemann-Pick disease type C, yet a fourth-quarter filing is still planned. The daily roundup covers Roche's fenebrutinib Priority

In this Huberman Lab Essentials episode, I explain how the neurochemicals epinephrine, acetylcholine and dopamine contribute to focus and concentration. I discuss tools for improving attention, including sleep, sound, structured work sessions, nutrition, caffeine and deliberate cold exposure. I also describe a brief daily meditation and visual focus exercises that train your ability to refocus when attention drifts. Additionally, I discuss the potential benefits and limitations of supplements,

Neuroscience Daily for 08 October follows 3 stories from r/neuro and r/neuroscience, moving through optogenetics nobel, dopamine reward signals, social pain codes.Chapters 00:00:00 — Intro 00:00:11 — Optogenetics Nobel 00:01:12 — Dopamine Reward Signals 00:02:06 — Social Pain Codes 00:03:01 — Closing 1. Optogenetics Nobel Beezloop reports that a Stanford psychiatrist is sharing the Nobel Prize in Medicine for work that helped turn light into a way of controlling brain cells. The

Hey! I'd love to hear your thoughts, send me a voice note.Dr. Toll is the founder of Compassion Neuroscience, where he combines TMS with neuroimaging methods such as EEG to treat patients with depression, anxiety, PTSD, and OCD. His evidence-based approach emphasizes quantitative measures to enhance patient outcomes and expand access to care—particularly for Gold Star families. Dr. Toll earned his PhD in Bioengineering from Stanford, specializing in TMS, EEG, and MRI. A West Point graduate, he

Michael speaks with Brady Holmer, the exercise scientist and 2:24 marathoner behind the Substack Physiologically Speaking, about which fitness trends hold up. Brady explains why he stopped taking creatine, which numbers on your wearable to ignore, and why endurance athletes now eat the carbs of three Cokes an hour. They discuss:(00:00) Preview(00:35) Why Brady stopped taking creatine(03:26) Creatine is oversold for the brain(09:14) The wearable numbers to ignore(12:47) The problem with HRV(16:14)